Needham Keeps a Buy Rating on Zimmer Biomet Holdings (ZBH)


Needham analyst Michael Matson maintained a Buy rating on Zimmer Biomet Holdings (ZBH) today and set a price target of $170. The company’s shares closed last Monday at $138.84, close to its 52-week high of $143.57.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.3% and a 62.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies Inc, Boston Scientific Corp, and Cardiovascular Systems.

Zimmer Biomet Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $147.27, representing a 7.0% upside. In a report issued on September 9, Wells Fargo also maintained a Buy rating on the stock with a $158 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $143.57 and a one-year low of $96.99. Currently, Zimmer Biomet Holdings has an average volume of 1.18M.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts